for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

MyMD Pharmaceuticals Inc

MYMD.OQ

Latest Trade

7.66USD

Change

0.07(+0.92%)

Volume

29,321

Today's Range

7.35

 - 

7.80

52 Week Range

3.31

 - 

10.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.59
Open
7.49
Volume
29,321
3M AVG Volume
4.52
Today's High
7.80
Today's Low
7.35
52 Week High
10.46
52 Week Low
3.31
Shares Out (MIL)
37.64
Market Cap (MIL)
285.69
Forward P/E
--
Dividend (Yield %)
--

Next Event

MyMD Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Akers Biosciences Says Joshua Silverman Appointed Chairman Of The Board

Intracoastal Capital Reports 7.5% Passive Stake In Akers Biosciences As Of November 17 - SEC Filing

Akers Biosciences And MyMD Pharmaceuticals Sign Definitive Merger Agreement

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About MyMD Pharmaceuticals Inc

MyMD Pharmaceuticals, Inc., formerly Akers Biosciences, Inc., is a clinical stage pharmaceutical company. The Company is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. MyMD-1 is being developed to treat age-related illnesses such as frailty and sarcopenia. MyMD-1 works by regulating the release of numerous pro-inflammatory cytokines, such as TNF-α, interleukin 6 (IL-6) and interleukin 17 (IL-17). Supera-CBD is a synthetic derivative of Cannabidiol (CBD) being developed to treat various conditions, including, but not limited to, epilepsy, pain and anxiety or depression.

Industry

Business Services

Contact Info

855 N. WOLFE STREET, SUITE 623

BALTIMORE, MD

21205

United States

+1.856.8488698

https://ir.mymd.com/

Executive Leadership

Joshua N. Silverman

Lead Independent Director, Chairman of the Board

Chris Chapman

President, Director, Chief Medical Officer

Ian Rhodes

Interim Chief Financial Officer

Paul Rivard

Executive Vice President, General Counsel

Adam Kaplin

Chief Scientific Officer

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
11.03
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-126.38
Return on Equity (TTM)
-115.03

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up